Literature DB >> 8103715

T cell activation and disease severity in HIV infection.

M Mahalingam1, M Peakman, E T Davies, A Pozniak, T J McManus, D Vergani.   

Abstract

In vitro studies have indicated that T lymphocyte activation may be of importance in the pathogenesis of HIV infection. In order to define the role of immune activation in vivo, we assessed the expression of the T cell activation markers HLA-DR and CD25 by flow cytometry in peripheral blood in relation to disease severity and the surrogate markers CD4 and beta 2-microglobulin in 157 patients with HIV infection and 53 healthy seronegative blood donors. Percentage levels of CD3+HLA-DR+ T lymphocytes were significantly higher (P < 0.0001) and percentage levels of CD3+CD25+ T lymphocytes significantly lower (P < 0.0001) in all HIV+ patients compared with controls. A significant correlation was observed between increasing percentage levels of CD3+HLA-DR+ T lymphocytes and both declining CD4 counts (r = 0.52; P < 0.001) and increasing beta 2-microglobulin levels (r = 0.56; P < 0.001). Percentage levels of CD4+HLA-DR+ and CD4+ CD25+ lymphocytes were significantly higher in all HIV+ patients compared with controls (P < 0.001). Levels of activated (HLA-DR+ and CD25+) CD4+ lymphocytes showed a significant step-wise linear increase with increasing disease severity (P < 0.001). High levels of CD3+HLA-DR+ T lymphocytes were found in a greater proportion (81.8%) of asymptomatic HIV+ patients (Centres for Disease Control (CDC) group II) than low CD4 counts (51.5%) (P < 0.001). Compared with controls, HIV+ patients had higher percentage levels of CD8+HLA-DR+ lymphocytes (P < 0.001), but similar levels of CD8+CD25+ lymphocytes. These results indicate that T cell activation is not only a consistent but also an early feature in HIV infection. Monitoring levels of activated T cells and their subsets is of value in assessing progression of HIV-related disease.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8103715      PMCID: PMC1554919          DOI: 10.1111/j.1365-2249.1993.tb08182.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  22 in total

1.  HIV. Tampering with transcription.

Authors:  G J Nabel
Journal:  Nature       Date:  1991-04-25       Impact factor: 49.962

2.  HIV revealed: toward a natural history of the infection.

Authors:  D Baltimore; M B Feinberg
Journal:  N Engl J Med       Date:  1989-12-14       Impact factor: 91.245

3.  Immune activation markers and AIDS prognosis.

Authors:  D H Osmond; S Shiboski; P Bacchetti; E E Winger; A R Moss
Journal:  AIDS       Date:  1991-05       Impact factor: 4.177

4.  Processing of the precursor of NF-kappa B by the HIV-1 protease during acute infection.

Authors:  Y Rivière; V Blank; P Kourilsky; A Israël
Journal:  Nature       Date:  1991-04-18       Impact factor: 49.962

5.  Serial CD4 lymphocyte counts and development of AIDS.

Authors:  A N Phillips; C A Lee; J Elford; G Janossy; A Timms; M Bofill; P B Kernoff
Journal:  Lancet       Date:  1991-02-16       Impact factor: 79.321

6.  HIV enhancer activity perpetuated by NF-kappa B induction on infection of monocytes.

Authors:  F Bachelerie; J Alcami; F Arenzana-Seisdedos; J L Virelizier
Journal:  Nature       Date:  1991-04-25       Impact factor: 49.962

7.  Patients with HIV infection have a reduced proportion of lymphocytes expressing the IL2 receptor p55 chain (TAC, CD25).

Authors:  H Zola; L Y Koh; B X Mantzioris; D Rhodes
Journal:  Clin Immunol Immunopathol       Date:  1991-04

8.  Early activation events render T cells susceptible to HIV-1-induced syncytia formation. Role of protein kinase C.

Authors:  N Mohagheghpour; R Chakrabarti; B S Stein; S D Gowda; E G Engleman
Journal:  J Biol Chem       Date:  1991-04-15       Impact factor: 5.157

9.  Activation of the complement system in human immunodeficiency virus infection: relevance of the classical pathway to pathogenesis and disease severity.

Authors:  G Senaldi; M Peakman; T McManus; E T Davies; D E Tee; D Vergani
Journal:  J Infect Dis       Date:  1990-12       Impact factor: 5.226

10.  Class II (DR) antigen expression on CD8+ lymphocyte subsets in acquired immune deficiency syndrome (AIDS).

Authors:  H W Ziegler-Heitbrock; D Stachel; T Schlunk; L Gürtler; W Schramm; M Fröschl; J R Bogner; G Riethmüller
Journal:  J Clin Immunol       Date:  1988-11       Impact factor: 8.317

View more
  33 in total

1.  Regeneration and tolerance factor: a correlate of human immunodeficiency virus-associated T-cell activation.

Authors:  T S Givens; B K DuChateau; J S Boomer; M P Westerman; A Gilman-Sachs; K D Beaman
Journal:  Clin Diagn Lab Immunol       Date:  1999-11

2.  Dynamics of CCR5 expression by CD4(+) T cells in lymphoid tissues during simian immunodeficiency virus infection.

Authors:  R S Veazey; K G Mansfield; I C Tham; A C Carville; D E Shvetz; A E Forand; A A Lackner
Journal:  J Virol       Date:  2000-12       Impact factor: 5.103

3.  Expression of MHC class II in T cells is associated with increased HIV-1 expression.

Authors:  M Saifuddin; G T Spear; C Chang; K A Roebuck
Journal:  Clin Exp Immunol       Date:  2000-08       Impact factor: 4.330

4.  Lack of evidence for small intestinal mucosal T-cell activation as a pathogenic mechanism in African HIV-associated enteropathy.

Authors:  A M Veitch; P Kelly; I Zulu; T T MacDonald; M J Farthing
Journal:  Dig Dis Sci       Date:  2001-05       Impact factor: 3.199

Review 5.  The role of cytokines in the pathogenesis and treatment of HIV infection.

Authors:  Marta Catalfamo; Cecile Le Saout; H Clifford Lane
Journal:  Cytokine Growth Factor Rev       Date:  2012-06-26       Impact factor: 7.638

6.  Identifying the target cell in primary simian immunodeficiency virus (SIV) infection: highly activated memory CD4(+) T cells are rapidly eliminated in early SIV infection in vivo.

Authors:  R S Veazey; I C Tham; K G Mansfield; M DeMaria; A E Forand; D E Shvetz; L V Chalifoux; P K Sehgal; A A Lackner
Journal:  J Virol       Date:  2000-01       Impact factor: 5.103

7.  HIV infection-associated immune activation occurs by two distinct pathways that differentially affect CD4 and CD8 T cells.

Authors:  Marta Catalfamo; Michele Di Mascio; Zonghui Hu; Sharat Srinivasula; Vishakha Thaker; Joseph Adelsberger; Adam Rupert; Michael Baseler; Yutaka Tagaya; Gregg Roby; Catherine Rehm; Dean Follmann; H Clifford Lane
Journal:  Proc Natl Acad Sci U S A       Date:  2008-12-05       Impact factor: 11.205

8.  Activation and coreceptor expression of T lymphocytes in HIV/AIDS patients of China.

Authors:  Hong Shang; Zining Zhang; Yongjun Jiang; Xiaoxu Han; Yanan Wang; Min Zhang; Xiaohui Ye; Ying Liu; Yingying Diao; Di Dai; Wenqing Geng
Journal:  J Clin Immunol       Date:  2005-01       Impact factor: 8.317

9.  Systemic dendritic cell mobilization associated with administration of FLT3 ligand to SIV- and SHIV-infected macaques.

Authors:  R Keith Reeves; Qing Wei; Jackie Stallworth; Patricia N Fultz
Journal:  AIDS Res Hum Retroviruses       Date:  2009-12       Impact factor: 2.205

10.  In vitro influence of Mycoplasma penetrans on activation of peripheral T lymphocytes from healthy donors or human immunodeficiency virus-infected individuals.

Authors:  Y Sasaki; A Blanchard; H L Watson; S Garcia; A Dulioust; L Montagnier; M L Gougeon
Journal:  Infect Immun       Date:  1995-11       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.